Critical observations on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosis
- 1 January 1993
- journal article
- case report
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 21 (6), 411-415
- https://doi.org/10.1002/mpo.2950210604
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- 131I-Metaiodobenzylguanidine in the Treatment of Neuroblastoma at DiagnosisJournal of Pediatric Hematology/Oncology, 1989
- Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development.Journal of Clinical Oncology, 1988
- Treatment of neuroblastoma with 131I‐MIBG: Dosimetric problems and perspectivesMedical and Pediatric Oncology, 1987
- Editorial: The treatment of neuroblastoma with131I-MIBGMedical and Pediatric Oncology, 1987
- Scintigraphic localization of a disseminated malignant pheochromocytoma with the use of 131I-meta-iodobenzylguanidineEuropean Journal of Nuclear Medicine and Molecular Imaging, 1984
- Histopathologic Prognostic Factors in Neuroblastic Tumors: Definition of Subtypes of Ganglioneuroblastoma and an Age-Linked Classification of NeuroblastomasJNCI Journal of the National Cancer Institute, 1984
- The treatment of neuroblastoma.Journal of Clinical Oncology, 1984
- High-dose melphalan with autologous marrow for treatment of advanced neuroblastomaBritish Journal of Cancer, 1982
- Long-Term Follow-up Results in Children and Adolescents Treated with Radioactive Iodine (131I) for HyperthyroidismNew England Journal of Medicine, 1975
- Long-Term Results of Treatment of Thyrotoxicosis in Children and Adolescents with Radioactive IodineNew England Journal of Medicine, 1970